Needham & Company LLC Cuts LivaNova (NASDAQ:LIVN) Price Target to $64.00

LivaNova (NASDAQ:LIVN) had its target price reduced by Needham & Company LLC from $75.00 to $64.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also recently weighed in on the stock. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday. Mizuho dropped their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Finally, Robert W. Baird increased their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $64.20.

LivaNova Trading Up 1.7 %

Shares of LIVN stock opened at $41.63 on Wednesday. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of 99.12 and a beta of 1.00. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a fifty-two week low of $40.37 and a fifty-two week high of $64.47. The firm’s 50 day moving average price is $47.40 and its two-hundred day moving average price is $49.49.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

A number of large investors have recently modified their holdings of the company. Jefferies Financial Group Inc. acquired a new stake in shares of LivaNova in the 4th quarter worth about $4,812,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of LivaNova by 25.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 153,458 shares of the company’s stock worth $7,107,000 after acquiring an additional 30,718 shares during the period. Squarepoint Ops LLC increased its holdings in shares of LivaNova by 74.3% in the 4th quarter. Squarepoint Ops LLC now owns 111,449 shares of the company’s stock worth $5,161,000 after acquiring an additional 47,494 shares during the period. Two Sigma Advisers LP increased its holdings in shares of LivaNova by 148.5% in the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock worth $9,936,000 after acquiring an additional 128,200 shares during the period. Finally, Two Sigma Investments LP increased its holdings in shares of LivaNova by 27.2% in the 4th quarter. Two Sigma Investments LP now owns 439,582 shares of the company’s stock worth $20,357,000 after acquiring an additional 93,985 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.